Miller Fisher Syndrome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review

Синдром Миллера—Фишера у пациентов с инфекцией, вызванной коронавирусом 2, вызывающим тяжелый острый респираторный синдром: систематический обзор
Adriano Antunes de Souza Araújo, Lucindo José Quintans‐Júnior, Paulo Ricardo Martins‐Filho, Victor Santana Santos, Ana Luiza Pereira de Andrade, Ana Júlia Pereira de Andrade, Maria Daniella Moura da Silva, Paula Santos Nunes, Lis Campos Ferreira, Eduardo Luís de Aquino Neves
2021-01-01

Guillain-Barré syndromeMiller Fisher syndromeSARS-CoV-2 infectionantiganglioside antibodiesintravenous immunoglobulin
BACKGROUND AND PURPOSE: Miller Fisher syndrome (MFS) is a subtype of Guillain-Barré syndrome characterized by the triad of ophthalmoparesis, areflexia, and ataxia. Although cases of MFS have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, no studies have synthesized the clinical characteristics of patients with this condition. METHODS: In this rapid systematic review, we searched the PubMed database to identify studies on MFS associated with SARS-CoV-2 infection. RESULTS: This review identified 11 cases, of whom 3 were hospitalized with motor and/or sensory polyneuropathy as the first sign of SARS-CoV-2 infection. SARS-CoV-2 RNA was not detected in analyses of cerebrospinal fluid, suggesting a mechanism of immune-mediated injury rather than direct viral neurotropism. However, antiganglioside antibodies were found in only two of the nine patients tested. It is possible that target antigens other than gangliosides are involved in MFS associated with SARS-CoV-2 infection. CONCLUSIONS: The present patients exhibited clinical improvement after being treated with intravenous immunoglobulin. Although rare, patients with SARS-CoV-2 infection may present neurological symptoms suggestive of MFS. Early recognition of the MFS clinical triad is essential for the timely initiation of treatment.
1
A rapid systematic review identified 11 reported cases of Miller Fisher syndrome associated with SARS-CoV-2 infection.
2
Antiganglioside antibodies were detected in only two of nine tested patients, suggesting that other target antigens may contribute to SARS-CoV-2-associated Miller Fisher syndrome.
3
Patients clinically improved after intravenous immunoglobulin treatment, emphasizing the importance of early recognition of the characteristic clinical triad.
4
SARS-CoV-2 RNA was absent from cerebrospinal fluid, supporting immune-mediated injury rather than direct viral neurotropism.
5
Three patients were hospitalized with motor and/or sensory polyneuropathy as the first manifestation of SARS-CoV-2 infection.

Miller Fisher syndrome associated with SARS-CoV-2 infection

Clinical characteristics, immune-mediated pathogenesis, and treatment response of Miller Fisher syndrome associated with SARS-CoV-2 infection

Publication Details
Publication Date
2021-01-01
Journal
Publisher
ISSN
Cited by
21
Access Type
Author Information
Authors
Adriano Antunes de Souza Araújo
Lucindo José Quintans‐Júnior
Paulo Ricardo Martins‐Filho
Victor Santana Santos
Ana Luiza Pereira de Andrade
Ana Júlia Pereira de Andrade
Maria Daniella Moura da Silva
Paula Santos Nunes
Lis Campos Ferreira
Eduardo Luís de Aquino Neves
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%